Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

22-02-2022 | ASCO GU 2022 | Conference coverage | Video

Add-on PARP inhibition in metastatic CRPC: PROpel and MAGNITUDE

David VanderWeele comments on the PROpel and MAGNITUDE trials investigating the addition of a PARP inhibitor to abiraterone in men with metastatic castration-resistant prostate cancer, focusing on the differences between the studies and the unanswered questions (5:20).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Related content

18-02-2022 | ASCO GU 2022 | Conference coverage | News

​​​​​​​PROpel: mCRPC patients benefit from add-on olaparib

18-02-2022 | ASCO GU 2022 | Conference coverage | News

Adding niraparib to abiraterone boosts mutated mCRPC outcomes
  • » This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.
Image Credits